Squarepoint Ops LLC acquired a new stake in shares of Passage Bio, Inc. (NASDAQ:PASG) in the third quarter, HoldingsChannel reports. The firm acquired 10,885 shares of the company’s stock, valued at approximately $143,000.
Several other institutional investors have also recently modified their holdings of PASG. FMR LLC grew its position in shares of Passage Bio by 52.1% during the second quarter. FMR LLC now owns 4,768,445 shares of the company’s stock valued at $130,321,000 after purchasing an additional 1,634,321 shares in the last quarter. Morgan Stanley purchased a new position in shares of Passage Bio during the first quarter valued at about $4,609,000. Bank of New York Mellon Corp bought a new position in shares of Passage Bio in the 2nd quarter valued at about $4,707,000. BlackRock Inc. lifted its holdings in shares of Passage Bio by 7.6% in the 3rd quarter. BlackRock Inc. now owns 1,513,269 shares of the company’s stock valued at $19,839,000 after acquiring an additional 106,455 shares during the last quarter. Finally, Granite Point Capital Management L.P. bought a new position in shares of Passage Bio in the 3rd quarter valued at about $1,311,000. Hedge funds and other institutional investors own 69.43% of the company’s stock.
A number of brokerages recently commented on PASG. Smith Barney Citigroup began coverage on shares of Passage Bio in a report on Friday, December 11th. They issued a “neutral” rating and a $2.21 price target for the company. Chardan Capital reaffirmed a “buy” rating and issued a $32.50 price target on shares of Passage Bio in a report on Thursday, November 12th. Zacks Investment Research raised shares of Passage Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. BidaskClub downgraded shares of Passage Bio from a “buy” rating to a “hold” rating in a report on Friday. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell assumed coverage on shares of Passage Bio in a report on Friday, December 11th. They issued a “neutral” rating and a $28.00 price target for the company. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Passage Bio currently has a consensus rating of “Hold” and an average price target of $23.78.
Shares of NASDAQ PASG opened at $25.57 on Friday. Passage Bio, Inc. has a 1 year low of $8.09 and a 1 year high of $38.23. The firm has a 50-day simple moving average of $22.95 and a two-hundred day simple moving average of $19.74.
Passage Bio (NASDAQ:PASG) last posted its quarterly earnings results on Sunday, November 15th. The company reported ($0.63) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.13. On average, sell-side analysts predict that Passage Bio, Inc. will post -2.98 earnings per share for the current fiscal year.
About Passage Bio
Passage Bio, Inc, a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies.
Read More: What is a Leveraged Buyout (LBO)?
Want to see what other hedge funds are holding PASG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Passage Bio, Inc. (NASDAQ:PASG).
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.